Seven approved drugs, three billion dollars in annual revenue, two FDA warning letters, and a set of forecasts that grow larger the further they travel from their source
FROM THE CRAIG BUSHON SHOW MEDIA TEAM
Most Americans have never heard the term RNA interference, usually shortened to RNAi, which is a strange thing to say about a class of medicine that has been approved and prescribed in the United States since 2018. The Food and Drug Administration’s own fiscal year 2025 materials identify seven approved small interfering RNA (siRNA) therapeutics — patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, and fitusiran — treating conditions that range from a rare inherited nerve disorder to high cholesterol to hemophilia. This is not an emerging technology in the speculative sense. It is an established one that arrived without much public attention, which means the questions worth asking are no longer about whether it works but about how its results are being described to patients, what it costs, and who gets it.
The underlying biology is more approachable than the terminology suggests. Every cell contains DNA, but DNA does not build proteins directly; messenger RNA carries the instructions from the DNA to the cellular machinery that assembles them, functioning as the courier in the process. Small interfering RNA works by directing the cell’s own machinery to degrade a specific, complementary messenger RNA molecule, which reduces production of the protein that molecule was meant to encode. The distinction that matters here, and the one most likely to get blurred in casual coverage, is that this is suppression of a message rather than correction of the source. RNAi reduces production of a selected protein by degrading its messenger RNA; it does not alter the underlying DNA sequence. It is a different mechanism from CRISPR gene editing, from antisense oligonucleotides, from mRNA vaccines, and from RNA editing, and the habit of collapsing all of these into a single story about genetic medicine does real damage to public understanding.
The commercial case no longer requires any forecasting at all, which is worth pausing on. Alnylam Pharmaceuticals, the company that brought the first RNAi drug to market, reported approximately $2.99 billion in global net product revenue for 2025 in its annual filing with the Securities and Exchange Commission, an increase of 81 percent over the prior year. Its first quarter of 2026 brought total revenue of roughly $1.036 billion, of which about $910 million was net product revenue. The annual figures come from Alnylam’s audited financial statements and the quarterly figures from its reported earnings release rather than from any analyst model, and together they establish the point that market projections are usually deployed to establish: this category has reached genuine commercial scale. A single quarter should not be annualized mechanically, since launch timing, inventory stocking, pricing, and geographic mix all move those numbers, but the trajectory is not in question.
Which brings us to the forecasts, and to a problem worth examining on its own terms. Three separate research firms have published 2035 projections for this space, and they do not agree. Towards Healthcare projects the RNAi therapeutics market reaching roughly $5.9 billion by 2035. Roots Analysis projects approximately $9.1 billion by the same year. SNS Insider projects around $13.63 billion by 2035, but for what it labels the RNAi technology market — a category that appears to sweep in research tools, platforms, and services well beyond therapeutics. Three numbers, three definitions, and none of the published summaries disclose the product-level assumptions, pricing models, or adoption rates underneath them. A figure above $30 billion also circulates in discussions of this sector, and our review could not locate a named source, publication date, or methodology behind it. Until those elements are documented, that number should not be repeated by anyone, including us. This is how a projection becomes a fact in public discourse: it gets quoted without its definition, then quoted again without its source, and the qualifiers fall away a little more with each retelling.
The regulatory record is where this story earns its watchdog attention, because it contains something rarer than a breakthrough — it contains a documented dispute over what a breakthrough actually delivered. In September 2023, Alnylam asked the FDA to extend patisiran’s label to cover ATTR cardiomyopathy, a heart condition, on the strength of the APOLLO-B trial. An FDA advisory committee voted nine to three that the benefits outweighed the risks. The agency declined to approve it anyway. FDA reviewers characterized the statistically significant benefits as small, found no demonstrated treatment effect for key endpoints among patients also taking tafamidis, and concluded that the uncertainty prevented any judgment about cardiovascular events or survival. Advisory committee votes are recommendations and the agency retains the decision, so this was a lawful exercise of authority rather than an irregularity. But the substance of it deserves more attention than it received, because the reviewers drew a line that the broader conversation about medical innovation almost never draws: a result can be statistically significant and still not be clinically meaningful. Alnylam subsequently won approval in March 2025 for vutrisiran in that same cardiomyopathy indication, on the basis of a different clinical program. The system worked, and it worked by saying no first.
The promotional record tells a related story, and it is not a single incident. On September 9, 2025, the FDA’s Office of Prescription Drug Promotion issued an untitled letter to Alnylam over a direct-to-consumer television commercial for vutrisiran, which the agency found misleadingly suggested the drug would broadly improve patients’ overall quality of life — a benefit that had not been demonstrated. Alnylam pulled the advertisement, and by late November the FDA confirmed the violations had been addressed. Then it happened again. In a letter dated April 23, 2026, the same office cited the drug’s consumer website, which carried the headline claim “Proven to help people with ATTR-CM live longer” alongside figures showing a 36 percent lower risk of death and an 80 percent survival rate at three and a half years against 72 percent for the placebo group. The problem was the provenance of those numbers: they came not from the double-blind, placebo-controlled portion of the HELIOS-B trial but from an open-label extension in which every participant, including the former placebo arm, was receiving the drug. Reviewers concluded the extension was inadequately designed to support conclusions about all-cause mortality over that timeframe, and determined the page misbranded the product. Alnylam had included a disclosure noting the analysis fell outside the original study plan. The agency was unmoved, on the principle that accurate fine print does not repair a misleading headline.
None of this establishes that RNAi is oversold as a science. It establishes that the gap between what a therapy demonstrates and how that therapy gets described is a live, recurring, documented problem at the industry’s most successful company, and that the FDA has had to intervene twice in eight months to close it. Readers encountering enthusiastic coverage of gene-silencing medicine should hold that context.
There is also a technical constraint that rarely survives translation into popular coverage. Delivering therapeutic RNA into the right tissue, in sufficient concentration, without triggering degradation or unacceptable immune effects, remains the central engineering problem in the field. The approved products cluster heavily in targets reachable through liver-directed delivery chemistry, which is why the success stories share a common anatomy. Research is underway across cancers, neurological illness, eye disease, and metabolic conditions, and those programs are real, but a clinical trial listing establishes that a study exists and nothing more. It does not establish safety, effectiveness, commercial viability, or eventual approval, and treating pipeline breadth as a preview of routine future care is exactly the error the patisiran cardiomyopathy decision should have taught the industry’s observers to avoid.
That constraint is also why the significance of this field should not be measured by counting approved medicines. The earliest products targeted rare conditions because those diseases offered clearer biological targets, smaller trial populations, and a regulatory path built for exactly that situation. The direction of travel is toward diseases affecting millions rather than thousands, and inclisiran is the proof that the transition has already begun — it is an siRNA therapy prescribed to lower LDL cholesterol, which is not a rare disease by any definition. As delivery chemistry improves, more of that migration becomes possible, and it would reshape the economics of the field as thoroughly as it reshapes the medicine. A therapy priced for a few thousand patients with an inherited disorder becomes an entirely different question for public and private budgets when the same class of drug is prescribed for common cardiovascular and metabolic conditions, and that question has not been seriously worked through in public.
Artificial intelligence belongs in this story, but with more restraint than it is usually granted. AI systems are demonstrably being used for target selection, sequence design, protein structure prediction, trial analytics, and laboratory automation, and that work is substantive. What the public record does not currently support is any specific claim about how much time or money these tools have removed from RNAi development, or how often computationally designed sequences have outperformed conventionally designed candidates in prospective human trials. Developers hold that comparison data internally. No standardized, independently audited industry dataset was located in our review. Anyone citing a percentage reduction in development cost or timeline should be asked immediately where the number came from.
Reading Between the Lines
Here at The Craig Bushon Show, we don’t just follow the headlines. We read between the lines to get to the bottom line of what’s really going on. The bottom line is that RNA interference is a real and commercially proven class of medicine whose promotion has twice required federal correction, whose market size is unknown to the public because the firms modeling it do not disclose their assumptions, and whose net prices are effectively unknowable because manufacturers, pharmacy benefit managers, insurers, and government programs each hold a different fragment of the transaction. We could not determine from the public record how these drugs are actually being distributed by diagnosis, geography, payer type, or income. That opacity is not an accident of an immature market; it is the ordinary operating condition of American pharmaceutical pricing, now extending itself into a technology that may eventually move from rare disease into high-prevalence cardiovascular and metabolic conditions where the budget implications are enormous. The science has moved considerably faster than the disclosure surrounding it, and the questions that will determine whether ordinary Americans actually benefit — what these drugs cost after every rebate and confidential contract, who is receiving them, and how a market this opaque is supposed to be measured at all — are precisely the ones nobody is currently required to answer.
